Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065375 · ClinicalTrials.gov registry record · Phase 2
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT02065375 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 109 participants.
The verdict
NCT02065375, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
Interventions
- DRUG Placebo
- DRUG Omaveloxolone Ophthalmic Suspension 1.0%
- DRUG Omaveloxolone Opthalmic Suspension 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2014-02-28 |
| Est. Completion | 2014-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065375
The ClinicalTrials.gov registry entry for NCT02065375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02065375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02065375 about?
NCT02065375 is a clinical study titled "RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery". This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
What is the current status of trial NCT02065375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2014-02-28. Estimated completion is 2014-09-30.
What interventions are being tested in trial NCT02065375?
The interventions under investigation include: Placebo (DRUG), Omaveloxolone Ophthalmic Suspension 1.0% (DRUG), Omaveloxolone Opthalmic Suspension 0.5% (DRUG).
Who is sponsoring clinical trial NCT02065375?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.